当前位置：
X-MOL 学术
›
Chem. Bio. Drug Des.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Efficacy studies of Sclerotium rolfsii lectin on breast cancer using NOD SCID mouse model.
Chemical Biology & Drug Design ( IF 3.2 ) Pub Date : 2018-05-31 , DOI: 10.1111/cbdd.13314 Prajna Hegde 1 , Jagadeesh Narasimhappagari 1 , Bale M Swamy 1 , Shashikala R Inamdar 1
Chemical Biology & Drug Design ( IF 3.2 ) Pub Date : 2018-05-31 , DOI: 10.1111/cbdd.13314 Prajna Hegde 1 , Jagadeesh Narasimhappagari 1 , Bale M Swamy 1 , Shashikala R Inamdar 1
Affiliation
|
Expression of altered glycans such as TF, Tn, and sTn antigens has been observed in a number of carcinomas which are targeted in cancer therapy. Sclerotium rolfsii lectin (SRL) is known to recognize TF and its substituted forms. Clinical potential of SRL has been demonstrated by studying its interaction with different types of cancer cells. Here we report, in vitro studies of SRL on breast cancer MDA-MB-468 cells and in vivo studies with MCF-7 xenografts. In vitro growth inhibitory studies of SRL on metastatic triple negative breast cancer MDA-MB-468 cells were performed by MTT assay, flow cytometry, adhesion, and CAM assay. In vivo efficacy studies of SRL were performed using NOD SCID mice bearing MCF-7 xenografts. SRL has strong binding to MDA-MB-468 cells with MFI of 85.5 and has growth inhibitory effect with IC50 of 32 μg/ml at 48 hr. SRL has antiangiogenesis effect and also anti adhesive effect with fibronectin and collagen at 20 μg/ml by 36% and 42%, respectively. In vivo efficacy studies of SRL on NOD SCID mice bearing MCF-7 xenogratfs revealed 61.77% and 75.71% tumor regressing effect, respectively, at 20 and 30 mg/kg body weight without any toxicity. All these results substantiate clinical potential of SRL on breast cancer.
中文翻译：
使用NOD SCID小鼠模型研究罗氏菌菌凝集素对乳腺癌的疗效。
已经在许多靶向癌症治疗的癌症中观察到改变的聚糖如TF，Tn和sTn抗原的表达。已知罗氏菌菌凝集素（SRL）可以识别TF及其取代形式。通过研究SRL与不同类型癌细胞的相互作用，已证明了SRL的临床潜力。在这里，我们报道了针对乳腺癌MDA-MB-468细胞的SRL的体外研究以及与MCF-7异种移植物的体内研究。通过MTT测定，流式细胞术，粘附和CAM测定进行了SRL对转移性三阴性乳腺癌MDA-MB-468细胞的体外生长抑制研究。SRL的体内功效研究是使用带有MCF-7异种移植物的NOD SCID小鼠进行的。SRL具有与MDA-MB-468细胞的强结合，MFI为85.5，并在48小时具有32μg/ ml的IC50的生长抑制作用。SRL具有抗血管生成作用，并且与纤连蛋白和胶原蛋白的抗粘连作用分别为20μg/ ml，分别为36％和42％。SRL对带有MCF-7异种移植物的NOD SCID小鼠的体内功效研究显示，在20和30 mg / kg体重下，肿瘤消退作用分别为61.77％和75.71％，无任何毒性。所有这些结果证实了SRL在乳腺癌中的临床潜力。
更新日期：2018-05-31
中文翻译：
使用NOD SCID小鼠模型研究罗氏菌菌凝集素对乳腺癌的疗效。
已经在许多靶向癌症治疗的癌症中观察到改变的聚糖如TF，Tn和sTn抗原的表达。已知罗氏菌菌凝集素（SRL）可以识别TF及其取代形式。通过研究SRL与不同类型癌细胞的相互作用，已证明了SRL的临床潜力。在这里，我们报道了针对乳腺癌MDA-MB-468细胞的SRL的体外研究以及与MCF-7异种移植物的体内研究。通过MTT测定，流式细胞术，粘附和CAM测定进行了SRL对转移性三阴性乳腺癌MDA-MB-468细胞的体外生长抑制研究。SRL的体内功效研究是使用带有MCF-7异种移植物的NOD SCID小鼠进行的。SRL具有与MDA-MB-468细胞的强结合，MFI为85.5，并在48小时具有32μg/ ml的IC50的生长抑制作用。SRL具有抗血管生成作用，并且与纤连蛋白和胶原蛋白的抗粘连作用分别为20μg/ ml，分别为36％和42％。SRL对带有MCF-7异种移植物的NOD SCID小鼠的体内功效研究显示，在20和30 mg / kg体重下，肿瘤消退作用分别为61.77％和75.71％，无任何毒性。所有这些结果证实了SRL在乳腺癌中的临床潜力。
京公网安备 11010802027423号